FDA Lifts Hold on Zentalis' Azenosertib Trials, Paving Way For New Cancer Treatment

Zentalis® Pharmaceuticals, Inc., a company focused on developing innovative cancer therapies, has announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on its azenosertib studies. This novel, oral WEE1 inhibitor can now continue its clinical trials without any changes to the original development plan. Zentalis is set to collaborate with trial investigators to restart the azenosertib studies promptly.

At an upcoming corporate event later this year, Zentalis will showcase new data on azenosertib monotherapy and share the latest updates on its clinical development and data presentation schedules. The company is set to adhere to its previously announced data milestones for the rest of 2024.

Kimberly Blackwell, M.D., Chief Executive Officer, said in a statement “We are grateful to the FDA for their collaboration and review of our complete response package, which included a comprehensive safety assessment of the azenosertib program. We are extremely pleased with the successful resolution of the partial clinical hold. Our confidence in the therapeutic index of azenosertib has been unwavering, and we continue to believe in the potential for this treatment to address unmet medical needs faced by people living with gynecologic malignancies.”